Prilenia Therapeutics B.V., a biopharmaceutical company that aims to accelerate progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms o...